MON-LB027 Clinical Case of Using GH-Method: Math-Physical Medicine to Control Type 2 Diabetes Patient via Both Lifestyle Management and Effective Medication

Abstract

Introduction: This clinical case is based on a 46-year-old female with type 2 diabetes (T2D). Her health data for a period of 174 days (from 9/11/2018 to 2/11/2019) are listed as follows: Weight (BMI): 202 / 175 lbs. BMI: 30.7 / 26.4 FPG: 159 / 109 mg/dL PPG: 200 / 120 mg/dL Daily glucose: 164 / 117 mg/dL A1C: 8.9% / 6.0% Method: This particular patient has been following the guidelines outlined from published findings, conclusions, and recommendations of the GH-Method: math-physical medicine approach (MPM), which utilized the developed AI Glucometer tool to predict and control her T2D conditions. Results: Here are the major data facts and condition improvements for this patient: (1) Weight reduced by 27 lbs. within 5 months. (2) As a direct result from weight reduction, her FPG has also decreased by 50 mg/dL. (3) Weight and FPG have a very high correlation of 89%. (3) PPG decreased by 80 mg/dL. It has a 46% correlation with her carbs/sugar intake (15 gram, low-carbs diet) and -53% correlation with post-meal walking (2,179 steps and ~20 minutes). (4) The accuracy of predicted glucose (120.21 mg/dL) vs. measured glucose (125.65 mg/dL) is 96%; however, their correlation is only 61% due to some missing or incorrect data input around November 2018. (5) This patient utilized the author's developed AI Glucometer which has learned sufficient local food information to be able to predict PPG extremely accurate (96%). As a comparison, the author's PPG prediction model has 99.3% accuracy and 82% correlation based on his collected 3,992 meals data (53% US and 47% international). Prior to the trial on GH-Method: math-physical medicine and AI tool, her medications included- - Metformin 1000 mg 1 BD - Sitagliptin 100 mg 1 OD - Glimepride 4 mg 1 OD - Voglobose 0.2 mg 1 BD - Atorvastatin 10 mg 1 OD - Aspirin 80 mg 1 OD - Empagliflozin 12.5 mg OD As she refused the insulin therapy suggested , oral agent Empagliflozin was added. Within 2 to 3 months of trial her medications were reduced. The sulphinylurea ( glimepride ) has been discontinued and followed by reduction of other OADs, such as Metformin reduced to 500mg BD and sitagliptin to 50 mg OD as her fasting blood sugar was around 90. Conclusion: By using the GH-Method: math-physical medicine and AI tool, along with following the physician's methodical medication treatment plan, this T2D patient has achieved significant improvement on controlling her diabetes conditions within five months. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. s presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.